Search for Clinical Trials | National Jewish Health

Select a Condition or Specialty

All Clinical Trials

Differences in the Pulmonary Artery of People with Pulmonary Hypertension

Pulmonary hypertension and pulmonary arterial hypertension are two conditions that can cause increased blood pressure within the lungs. The differences between the two conditions on a cellular level are not well understood, and researchers are evaluating cell samples from people that are undergoing a right heart catheterization to learn more about these two diseases and improve future care.

Gender: Any
Ages: 18+
Compensation: Not Provided
Time Required: One visit to review and sign consent before scheduled procedure and three follow-up phone calls (once a year for three years).

More Information

Effects of Keto Diet in People with HFpEF

The keto diet has helped many people lose weight and improve their overall health. Researchers are investigating if it can also benefit people with a specific type of heart failure.

Gender: Any
Ages: 21-79
Compensation: Provided
Time Required: 12-week post-study testing is complete. There will be an option to enroll in a 12-week extension arm (for a total of 24 weeks). Primary study commitment will involve a total of 9 visits

More Information

New Trial Medication for Pulmonary Arterial Hypertension

By adding a new investigational Pulmonary Arterial Hypertension (PAH) medication to your current therapy, you could experience relaxed and widened artery walls.

Gender: Any
Ages: 18-75
Compensation: Provided
Time Required: Up to 42 months

More Information

Pulmonary Arterial Hypertension & increased dose of Opsumit

The UNISUS study will compare the effectiveness and safety of a higher dose of an investigational medication called Opsumit to a lower dose in people with pulmonary arterial hypertension (PAH). The results of the UNISUS Study will provide more information about the investigational medication’s effectiveness and safety when it is given as a higher dose to adults with PAH.

Gender: Any
Ages: 18+
Compensation: Provided
Time Required: Up to 4 years. Year 1: monthly visits. Year 2: visits every three months. Years 3-4: visits every six months.

More Information

Adult Trials

New Trial Medication for Pulmonary Arterial Hypertension

By adding a new investigational Pulmonary Arterial Hypertension (PAH) medication to your current therapy, you could experience relaxed and widened artery walls.

Gender: Any
Ages: 18-75
Compensation: Provided
Time Required: Up to 42 months

More Information

Pulmonary Arterial Hypertension & increased dose of Opsumit

Gender: Any
Ages: 18+
Compensation: Provided
Time Required: Up to 4 years. Year 1: monthly visits. Year 2: visits every three months. Years 3-4: visits every six months.

More Information

Search Clinical Trials

Select a Condition or Specialty

All Clinical Trials

Differences in the Pulmonary Artery of People with Pulmonary Hypertension

Effects of Keto Diet in People with HFpEF

New Trial Medication for Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension & increased dose of Opsumit

Adult Trials

New Trial Medication for Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension & increased dose of Opsumit

Pediatric Trials

Healthy Participant Trials